Expertise in
35
conditions

Dr. Daniel R. Greenwald

Oncology
Steven Zelko
309 W Quinto St, 
Santa Barbara, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
35
conditions
Steven Zelko
309 W Quinto St, 
Santa Barbara, CA 

Overview

Daniel Greenwald is an Oncologist practicing medicine in Santa Barbara, California.

Dr. Greenwald is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Chronic Familial Neutropenia, Non-Hodgkin Lymphoma, and Familial Colorectal Cancer.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 6 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Barbara Cottage Hospital
Santa Ynez Valley Cottage Hospital
Goleta Valley Cottage Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Steven Zelko
309 W Quinto St, Santa Barbara, CA 93105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

9 Total Publications

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Journal: Blood advances
Published: September 17, 2025
Similar Doctors
Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

111 E Victoria St, 
Santa Barbara, CA 
 (1.3 miles away)
805-563-0041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Juliet Penn is an Oncologist practicing medicine in Santa Barbara, California. Dr. Penn is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Paget Disease of the Breast, Angiosarcoma, and Bone Marrow Aspiration.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

W Michael Hogan MD PC

2900 Loma Vista Rd Ste 205, 
Ventura, CA 
 (30.4 miles away)
805-642-4830
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Hogan is an Oncologist practicing medicine in Ventura, California. Dr. Hogan is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Malignant Mixed Mullerian Tumor, and Testicular Yolk Sac Tumor. Dr. Hogan is board certified in Gynecologic Oncology. Dr. Hogan is currently accepting new patients.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required

Steven Zelko

309 W Quinto St, 
Santa Barbara, CA 
 (0.1 miles away)
805-563-0041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Frederic Kass is an Oncologist practicing medicine in Santa Barbara, California. Dr. Kass is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Paget Disease of the Breast, Breast Cancer, and Pancreatic Cancer.

Frequently Asked Questions about Dr. Daniel R. Greenwald

How do I make an appointment with Dr. Daniel R. Greenwald?

You can book an appointment with Dr. Daniel R. Greenwald by calling their office at 805-563-0041. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel R. Greenwald a top-rated expert for Severe Congenital Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel R. Greenwald is classified as an Distinguished expert for Severe Congenital Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel R. Greenwald specialize in?

While Dr. Daniel R. Greenwald is a Oncology, they have specific expertise in Severe Congenital Neutropenia, Chronic Familial Neutropenia, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Daniel R. Greenwald participate in research or clinical trials?

Yes. Dr. Daniel R. Greenwald has published 9 articles and abstracts on conditions like Severe Congenital Neutropenia. You can view a list of Dr. Daniel R. Greenwald's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel R. Greenwald accept my insurance?

Dr. Daniel R. Greenwald accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 805-563-0041 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenwald's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 24 Advanced Conditions
    View All 57 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile